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Hematotoxicity of magnetite nanoparticles coated with dimercaptosuccinic acid (DMSA) and 
polyethylene glycol (PEG) has been evaluated by determining their safety in vitro and in vivo 
in a rat model up to 30 days after administration of a single dose.  The in vitro analysis consists 
on global plasma coagulation (PT, aPTT, Fibrinogen) and platelet aggregation tests while the 
hematotoxicity studies in vivo include a complete blood count and the possible genotoxic 
effects analysis in the bone marrow hematopoietic function.  Prolonged aPTT values indicate 
higher anticoagulant effect for NP-DMSA compared with PEG-coated nanoparticles as a 
consequence of the higher surface charge of the former.  The in vivo tests showed that these 
bioferrofluids do not cause genotoxic effects, affect erythropoiesis or increase the number of 
immature erythrocytes in the bone marrow at the analyzed dose.  However, nanoparticles 
administration showed a significant effect on the leukocytes counts in animals treated with 
DMSA coated nanoparticles 24 h after injection.  This response is not observed in animals 
treated with PEG modified nanoparticles which justifies the use of this polymer in biomasking 
strategies. 
 
Keywords: magnetic nanoparticles, toxicity, PEG coated nanoparticles, blood, hematological 
parameters 
 
 
 
 
 
 
Introduction 
Magnetic nanoparticles based on iron oxides are being used as 
contrast agents in magnetic resonance imaging (MRI).  Clinical 
applications of these materials in drug delivery, hyperthermia and 
diagnosis are also being considered seriously1.  However, a first 
requisite for in vivo applications is blood compatibility2, otherwise 
these materials would be immediately discarded for intravenous 
administration.  
Interactions of nanoparticles with blood usually start with protein 
adsorption3, and subsequently derive in coagulation problems and 
other disturbances.  Several studies have reported that environmental 
nanoparticles significantly increase the risk and worsen the 
prognosis of cardiovascular diseases due to the induction of 
thrombotic complications4.  Protein adsorption is favored by surface 
charges, especially positive charges, and can be minimized with an 
appropriate coating.  Carbohydrates and other biological polymers 
have been considered to be effective against protein adsorption, 
although polyethylene glycol is the preferred coating for these 
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purposes5, 6.  However there are only few studies investigating the 
hematological effects of nanoparticles in vivo in spite of the fact that 
the majority of nanoparticle formulations are intended for systemic 
administration in clinical applications.  In addition, there are no 
standard methodologies for the in vitro assessment of the blood 
compatibility of these nanoproducts. 
The in vitro biocompatibility studies should also include evidence of 
hemolysis.  The unique physicochemical properties of the 
nanoparticles could cause hemolysis by acting on the membrane of 
red blood cells.  Several studies have revealed the effect of the 
nanoparticles on the blood by measuring their hemolytic action in 
vitro7.  However, direct results interpretation of these studies is 
complicated due to variability of the experimental conditions such as 
incubation time of blood with the nanoparticles, the wavelength at 
which the hemoglobin is quantified, the centrifugation forces, blood 
storage time and conditions and blood source (human or rabbit)8. 
Platelets are very sensitive to contact with biological substances, 
such as collagen, ADP and epinephrine, and non-biological ones, 
including ristocetin, that are commonly used in the hematology 
laboratory to detect functional defects of platelets.  Foreign materials 
and high shear stress can also induce platelet aggregation.  When this 
occurs they tend to produce micro aggregates that are easily detected 
by modern blood cell counters because they decrease the number of 
platelets and alter the size distribution curve.  Nanoparticles can 
potentially damage the cell membrane and even the cytoplasm since 
they can penetrate inside cells.  Blood cell counters not only quantify 
blood cells but also can detect abnormalities in shape, size and 
homogeneity.  
This study was designed specifically to investigate whether iron 
oxide magnetite nanoparticles with a narrow size distribution (Mean 
size=7 nm; SD < 0.15) coated with different polymers 
(Dimercaptosuccinic acid (DMSA) and Polyethylene glycol (PEG)) 
could lead to blood coagulation disorders and affect hematological 
parameters in vitro and in vivo.  These bioferrofluids have previously 
been used in biodistribution and pharmacokinetics studies in 
different animal models.  PEG coated nanoparticles have shown a 
good performance as MRI long circulating agents due to the effect of 
incorporation of PEG into the nanoparticle surface which is known 
to provide stealth coating to camouflage them, and thus, temporarily 
bypass recognition by macrophages9.  As with any device or 
pharmaceutical product, DMSA or PEG coated nanoparticles 
intended for biomedical application must also be subjected to 
extensive blood biocompatibility testing before regulatory approval 
for administration to patients.  To our knowledge, the blood 
biocompatibility of these products has not been established till date.  
Previous hematological studies on iron oxide nanoparticles coated 
with poly(4-vinyl pyridine)-polyethylene glycol (PVP-PEG) brush 
copolymers indicated a non-specific anticoagulant effect of the 
bioferrofluid10. 
We have carried out an extensive in vitro biocompatibility study of 
our bioferrofluids with blood including coagulation studies, 
hemolysis and quantification of leukocytes, erythrocytes and 
platelets, to rule out immediate cytotoxicity of nanoparticles or 
contact spontaneous platelet aggregation11-13.  Moreover, blood 
toxicity of these nanomaterials has been studied in terms of global 
tests (Prothrombin time (PT), activated partial thromboplastin time 
(aPTT), Fibrinogen), thrombus-elastography, platelet aggregation 
and degradation products of fibrinogen and fibrin.  Recently, a 
detailed description of methods has been published, which focuses 
on the global plasma coagulation tests (PT, aPTT, Fibrinogen) and 
platelet aggregation14.  The doses used in this study are higher than 
the therapeutically relevant concentration but describe the range 
where we observed an effect on hematological parameters.  The 
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recommended dosage for products like Feridex IV, Berlex 
Laboratories; and Endorem, Guerbet is 0.56 mg of iron per kg of 
body weight15.  It is also in the same range as those used in other 
cytotoxicity assays published previously16.  
Some studies have evaluated the compatibility of nanoparticles with 
the blood coagulation system17 in vivo in rats18 and rabbits19, while 
most of the authors have carried out only in vitro tests10-12, 20.  
Finally, we have carried out hematotoxicity studies in vivo including 
a complete blood count analysis and also possible genotoxic effects 
in the hematopoietic function of the bone marrow.  
 
Materials and methods  
Materials:  Iron (III) acetylacetonate, 1,2-dodecanediol, oleic acid, 
oleylamine, 1-octadecene, hexane, dimercaptosuccinic acid, ethanol, 
toluene, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride and O,O-bis(2-aminoethyl)-polyethylene glycol 2000 
Da were commercial products purchased from Sigma-Aldrich.  
Female Wistar rats (from 10-13 weeks old) weighing 300 g ± 20 g 
were purchased from CEMIB (Campinas), and were maintained 
under controlled conditions before and during the experiments (i.e., 
room temperature at 25 ºC; relative humidity of 65 %; 12 h 
light/dark cycle) in the Institute of Biological Science (University of 
Brasília) animals’ facility.  Access to food and water was provided 
ad libitum.  The present animal research was approved by the 
Animal Ethics Committee of the University of Brasília, Brazil.  For 
in vitro studies blood samples were obtained from healthy human 
volunteers. 
Magnetic nanoparticles preparation 
Magnetite nanoparticles were obtained via thermal decomposition of 
an iron coordination complex as a precursor to ensure nanoparticle 
homogeneity in size and shape following the method reported by 
Sun and co-workers21, 22.  Particle size and shape were studied using 
a 200 keV JEOL-2000 FXII microscope.  A drop of a dilute 
magnetic nanoparticle suspension in hexane was placed on a carbon 
coated copper grid and dried at 50ºC.  Size distribution was 
determined through manual measurement of more than 200 particles 
and data were analyzed with Gwyddion 3.25 software to obtain the 
mean size and standard deviation by gaussian fitting.  The 
superparamagnetic behavior of the nanoparticles was verified using a 
vibrating sample magnetometer (MLVSM9 MagLab 9T, Oxford 
Instruments).  Magnetization curves were recorded by saturating the 
sample in a 5 T field at room temperature and sweeping the field 
range between 5 and -5 T at 0.3 T/min. 
Particles were coated with meso-2,3-dimercaptosuccinic acid (NP-
DMSA) by a ligand exchange reaction to remove oleic acid, after 
which a short-chain diamine PEG was covalently bound to the 
nanoparticle surface via 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC) activation of the carboxylic acids 
(NP-PEG-(NH2)2).  Colloidal properties of 0.5 mM Fe nanoparticle 
suspensions in water were characterized by dynamic light scattering 
(DLS) using a Nanosizer ZS (Malvern).  Z-Average values in 
intensity at pH 7 were used as the mean hydrodynamic size.  The 
polydispersity degree index (PDI) was calculated by dividing the 
standard deviation by the mean size.  The Z potential was measured 
in a 0.01 M KNO3 solution.  Other properties of NP-DMSA and NP-
PEG-(NH2)2 have been described in detail in previous publications
16. 
Coagulation Studies 
Control plasma: Blood samples were obtained from healthy human 
volunteers. Samples were collected in citrate (0.129 M) vacutainer 
tubes.  The samples were centrifuged at 3500 rpm to obtain platelets-
poor plasma (PPP).  The plasma was processed for the coagulation 
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studies of aPTT and PT using the coagulometer TOP-ACL-TOP 700 
from IL-Instrumentation.  The results were within the reference 
limits (23-37 s. and 9-14 s. respectively). 
PPP treated with bioferrofluids: NP-DMSA and NP-PEG-(NH2)2 
were mixed with PPP making serial dilutions for final particle 
concentrations ranging from 0.3 to 0.05 g/L of iron, and processed 
for the measurement of PT and aPTT.  Blank samples of DMSA and 
DMSA-PEG-(NH2)2 were prepared containing similar concentration 
of these reactants as those in bioferrofluid samples.  
In order to find out the origin of the anticoagulant effect, samples 
that showed an increase of aPTT were tested by mixing them with 
normal plasma (mixing study), after that thrombin time and 
coagulation factors were measured.  Fibrinogen was measured by 
von Clauss method in PPP treated with bioferrofluids at high 
concentration (0.3 g/L Fe) using reactants and the coagulometer 
TOP-ACL both from IL-Instrumentation Laboratory. 
Complete blood counts (CBC) studies  
Control blood: Blood samples were obtained from healthy human 
volunteers. Samples were collected in EDTA K3, 1.8 mg/mL 
vacutainer.  The blood samples were processed for CBC studies 
using a Coulter LH 780 analyzer from Beckman Coulter.  
Blood treated with bioferrofluids: the investigated materials were 
mixed with the blood samples at dilutions 1:10 and 1:100 and 
processed for blood cell counting. 
Hemolysis studies  
Blood samples were obtained from healthy human volunteers.  
Samples were collected in Lithium heparin 17 UI/mL vacutainer 
tubes.  The samples were processed for the measurement of the free 
hemoglobin using a double beam spectrophotometer Analytic Jena-
Specord 205 with wavelength range between 500-630 nm. 
Hematology analysis in vivo 
Rats were randomly divided into three groups (n= 4/group), the 
control and the experimental groups: Animals treated with NP-
DMSA and animals treated with NP-PEG-(NH2)2.  The animals of 
the experimental groups received a single dose of magnetite 
nanoparticles (2.5 mg/kg B.W.) through the tail vein.  This dose is 
five times larger than the recommended one for commercial products 
(~0.5 mg/kg B.W.)14 but it is well below the doses used in many 
experimental works (10 mg/kg B.W)23.  Rats were anesthetized with 
a mixture of Ketamine/Xylazine and peripheral blood was collected 
at 24 hours, 7, 15 and 30 days after nanoparticles administration.  
Control animals were sacrificed progressively during the study.  
Blood collected in EDTA (10 %) was analyzed using a Sysmex 
pocH-100i™ Automated Hematology Analyzer. 
Genotoxicity test 
Comet Assay: The extent of DNA damage was determined via 
alkaline single cell gel electrophoresis according to N.P. Singh and 
cols.24 with some modifications.  Briefly, 60 µL of peripheral blood 
was mixed with 240 µL of 0.5% low melting point agarose. The 
mixture was pipetted into slides (2 slides/rat) precoated with 1.5% 
normal melting point agarose and covered with a coverglass.  Then, 
the slides were incubated in freshly prepared lysis buffer (NaCl 2.5 
M, EDTA 100 mM, Tris 10 mM, 1% Triton x-100, 10% DMSO) in 
the dark for 2 h at 4°C.  The slides were then placed in a horizontal 
electrophoresis tank containing fresh electrophoresis buffer (300 
mM NaOH, 1 mM EDTA, pH 13) and incubated for 30 min at 4°C.  
Electrophoresis was conducted for 30 min at 25 Volts and 300 mA.  
The slides were washed with neutralization solution (0.4 M Tris-
HCl, pH 7.5) and stored at 4°C until analysis.  Scoring was carried 
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out under blinded conditions by an individual not connected with the 
study.  The slides were stained with 60 µL of ethidium bromide (20 
µg/mL), coverslipped and cells were analyzed using a fluorescence 
microscope (ZEISS Axioskop 2-HAL 100) where 150 cells/rat were 
examined and classified.  The cells were classified, according to the 
size and proportion nucleoid-tail25, in levels of damage observed (0, 
1, 2, 3 and 4) to calculate the percentage of Total Damage (% TD) 
from Damage Index (DI) proposed by26.  
Citotoxicity and Micronucleus test: Bone marrow samples were 
suspended in fetal bovine serum (FBS).  The suspension was 
homogenized and then centrifuged at 1000 rpm for 10 minutes.  The 
supernatant was removed and the pellet was resuspended in 50 µL of 
FBS.  The smear was performed with 10 µL of homogenate per slide 
(2 slides/rat). Slides were air-dried at room temperature, fixed with 
methanol (10 min) and stained with Giemsa at 20% (12 min).  The 
stained slides were analyzed with a light microscope Olympus BH2.  
For each animal, 4000 cells were counted with a manual counter.  
The frequency of micronuclei was evaluated in 2000 polychromatic 
erythrocytes (PCE) and 2000 normochromatic (immature) 
erythrocytes (NCE), according to the OECD guideline 474 (1997).  
Cytotoxicity was assessed by the percentage of polychromatic 
erythrocytes PCE (% PCE); therefore, at the time of the populations 
of erythrocytes reached the mark of at 2000 cells during counting, 
the quantities of NCE and PCE were recorded and PCE% was 
calculated using the formula: 
 
Statistical analysis 
Data were analyzed by parametric or non-parametric statistics, 
according to the normal distribution using the Kolmogorov-Smirnov 
test.  For parametric data was performed Analysis of Variance 
(ANOVA) followed by Dunnett Multiple Comparisons test or t- test 
and nonparametric data were analyzed with the Mann-Whitney test. 
Statistical analysis data are summarized in Supplementary Material. 
 
Results and Discussion 
Particle Characterization 
Iron oxide nanoparticles used in this work were obtained via thermal 
decomposition of iron (III) acetylacetonate in 1-octadecene in the 
presence of oleic acid.  Particles were 7.5 nm in diameter, uniform in 
size (PDI = 0.16), relatively spherical and well dispersed due to the 
presence of oleic acid around the particles (Figure 1 A).  To study 
the magnetic properties of the nanoparticles, magnetization curves 
were performed for the NP-oleic acid in hexane.  The sample 
showed a superparamagnetic behavior with saturation magnetization 
values of 67 emu/ g Fe (Figure 1B).  This is an important advantage 
that enables nanoparticle stability and dispersion upon removal of 
the magnetic field as no residual magnetic force exists between the 
particles. Several biomedical and bioengineering applications require 
that nanoparticles have high magnetization values and hydrodynamic 
size smaller than 100 nm with overall narrow particle size 
distribution, so that the particles have uniform physical and chemical 
properties. 
Particles were coated with meso-2,3-dimercaptosuccinic acid (NP-
DMSA) after a ligand exchange reaction.  In order to increase the 
biocompatibility of the material NP-DMSA were chemically 
modified with PEG (NP-PEG-(NH2)2).  Properties of NP-DMSA and 
NP-PEG-(NH2)2 have been extensively described in previous 
publications9, 16.  DLS observations showed a monomodal 
distribution of DMSA coated particles with an average 
hydrodynamic diameter of 22 nm and polydispersity degrees (PDI) 
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lower than 0.25.  After PEG modification average hydrodynamic 
size at pH 7 is increased from 22 to 27 nm.  Surface charge 
decreased from approximately -35 mV for NP-DMSA samples to 
values between -15 mV for PEG-modified nanoparticles (Figure 1 C, 
D).  Nanoparticle size and surface chemistry and charge have a 
profound effect in the pharmacokinetic, biodistribution and 
toxicology of the product. 
Figure 1.  Nanoparticle Characterization.  (A) Transmission electron 
microscopy images of ~7 nm oleic acid coated nanoparticles.  (B) 
Magnetization curve at 250 K for oleic acid coated nanoparticles. 
(C) Hydrodynamic sizes for NP-DMSA (solid line) and PEG coated 
nanoparticles (dotted line).  (D) Evolution of Z-potential as a 
function of pH.  NP-DMSA [●], NP-PEG-(NH2)2 [■]. 
 
Coagulation studies for DMSA and PEG coated bioferrofluids  
The prothrombin time (PT) is a measurement of the extrinsic 
coagulation pathway, whereas the activated partial thromboplastin 
time (aPTT) is an indicator of the efficacy of both the intrinsic (now 
referred to as the contact activation pathway) and the common 
coagulation pathways.  Both PT and aPTT were measured on PPP 
treated with different concentrations of NP-DMSA or NP-PEG-
(NH2)2 bioferrofluids ranging from 0.05 g/L Fe to 0.3 g/L Fe.  
In the case of NP-DMSA treated plasma, the PT values are within 
our laboratory normal reference range (9-14 s).  In general, they are 
slightly lower than control values.  These results are plotted in 
Figure 2A. On the other hand, the aPTT shows a rapid increase as 
the NP-DMSA concentration increases.  For instance, at the lowest 
concentration, 0.05 g/L Fe, aPTT value is already 40.66 ± 5.23 s, 
significantly higher than the control one that is 29.17 ± 2.01 s, and at 
the highest concentration, 0.3 g/L Fe, aPTT value is 65.58 ± 6.13 s, 
more than double of the control value (Figure 2B).   
In the case of NP-PEG-(NH2)2 treated plasma, PT shows no 
significant difference for all concentrations tested (Figure 2A).  Even 
at the highest concentration, 0.3 g/L Fe, the PT value is 11.78 ± 1.95 
s that compares well with its control value 10.60 ± 1.26 s.  In 
contrast, aPTT shows a significant concentration-dependent increase 
in the whole Fe concentration range (Figure 2B), although, at 
concentrations of 0.07 g/L Fe and below, the aPTT values are still 
within the laboratory normal reference range (29-37 s).  At the 
highest concentration, 0.3 g/L Fe, aPTT value is already 49.37 ± 
8.71 s, well above the control value 29.41 ± 2.86 s.  
A prolonged aPTT suggests one of the following possibilities: a) 
deficiency of one or more coagulation factors; or b) presence of an 
inhibitor in plasma.  The usual procedure to elucidate which of the 
two options is ruling consists on mixing the abnormal plasma 
(plasma treated with nanoparticles) with normal plasma and then 
measuring the aPTT again. If the prolongation of aPPT disappears, 
there is a deficiency of one or more coagulation factors.  When the 
aPPT prolongation persists, it is indicative of the presence of an 
inhibitor.  In the latest case, it is important to find out if the 
inhibition effect is specific or non-specific using new tests, including 
thrombin time (TT) and quantifying the activity of factors that may 
be affected by the inhibitor at various dilutions. 
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In order to explore the cause of the aPTT prolongation, PPP treated 
with the highest concentration (0.3 g/L Fe) of NP-DMSA or NP-
PEG-(NH2)2 were used for the following studies: a) mixture tests, in 
which PPP treated with bioferrofluids were mixed with normal 
plasma (1:1), b) thrombin time (TT) measurements; and c) intrinsic 
coagulation factors (FVIII, FIX, FXI, and FXII) measurement.  
In the case of NP-DMSA treated plasma, it was observed that: a) the 
aPTT measurements for bioferrofluids treated plasma, returned to 
normal levels, 30.83 ± 0.74 s after mixing with normal plasma (1:1); 
b) The TT values were also normal; 27.83 ± 2.57 s compared to a 
control value of 21.83 ± 1.45 s (TT reference limits is 15-28 s.); c) 
and intrinsic coagulation factors decreased, from 126.70 ± 4.10 %, 
107.60 ± 26.87 %, 79.00 ± 11.46 %, 80.90 ± 0.42 % in the control to 
86.95 ± 8.56 %, 63.05 ± 15.20 %, 40.95 ± 6.58 % and 37.55 ± 
4.45% in the treated one for FVIII, FIX, FXI, and FXII, respectively.  
 
 
Figure 2.  The effect of NP-DMSA and NP-PEG-(NH2)2 on coagulation system: (A) Prothrombin time (B) Activated partial thromboplastin 
time, in seconds.  Values represent mean ± SD (n= 6 for bioferrofluids, 12 for PBS and 24 for control), (*) marks significant differences 
between bioferrofluids and control.  (C) The effect of NP-DMSA and NP-PEG-(NH2)2 on the von Clauss determined Fibrinogen in mg/dL.  
Values represent mean ± SD (n=3 for bioferrofluids, and 6 for control).  The effect of DMSA and PEG-(NH2)2 on coagulation system as free 
components: (D) Prothrombin time in seconds, (E) Activated partial thromboplastin time in seconds, and (F) Fibrinogen D in mg/dL.  Values 
represent mean ± SD (n=6 for DMSA and PEG-(NH2)2, and 12 for control).Control [ ], PBS [■], NP-DMSA [■], NP-PEG-(NH2)2 [■]. 
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In the case of NP-PEG-(NH2)2 treated plasma a similar trend was 
observed: a) the aPTT values returned to normal levels (33.40 ± 1.73 
s (mean ± SD) in the treated samples as compared to 29.33 ± 2.60 s); 
b) TT measurements also showed normal values (28.37 ± 1.59 s in 
the PPP treated with NP-PEG-(NH2)2; as compared to 24.03 ± 0.50 s 
in the control; and c) intrinsic coagulation factors decreased from 
99.50 ± 31.54 %, 110.05 ± 19.73 %, 90.75 ± 2.90 %, 81.80 ± 12.59 
% in control samples to 54.00 ± 16.55%, 50.00 ± 4.10%, 50.25 ± 
3.18 %, 54.05 ± 9.83% in treated samples,  for FVIII, FIX, FXI, and 
FXII. 
The prolonged aPTT values are probably due to an inhibition of 
intrinsic coagulation factors after nanoparticle addition27.  When 
nanoparticles are in contact with a biological fluid their surface will 
be covered with a “corona” of biological macromolecules.  Surface 
charge plays a fundamental role in this process, and this is evidenced 
by a higher inhibition effect of NP-DMSA compared with PEG-
coated nanoparticles. 
 
Fibrinogen measurements by von Clauss method 
To avoid the possible interference of the suspended nanoparticles on 
the fibrinogen derived method, which is based on light dispersion, 
the von Clauss method was also used.  The resulting measurements 
for PPP treated with NP-DMSA or NP-PEG-(NH2)2 at the highest 
concentration (0.3 g/L Fe), showed no significant difference with 
respect to control (Figure 2C).  Fibrinogen values were 227.67 ± 
30.07 mg/dL and 321.67 ± 10.97 mg/dL for NP-DMSA and NP-
PEG-(NH2)2 treated plasma respectively, and 261.33 ± 66.48 mg/dL 
for the control, which are not significantly different.  
Taking together all these results (normal Fibrinogen values, normal 
values of intrinsic coagulation factors (FVIII, FIX, FXI, and FXII) 
and the factors in the common coagulation pathway), a possible case 
of Disseminated Intravascular Coagulation (DIC)-like toxicity in 
vivo can be discarded.  It is also necessary to emphasize that the 
coagulation study was performed using a nanoparticles’ amount 
much higher than those used in clinical applications.  
 
Coagulation studies for separated components (DMSA and 
PEG-(NH2)2)  
For this purpose, DMSA and PEG-(NH2)2 blank samples were 
prepared.  Thermogravimetric analysis previously reported16 allows 
the preparation of different samples containing similar concentration 
of these compounds as those present in the nanoparticles.  These 
solutions were mixed with PPP in different concentrations: 0.01 and 
0.1 g/L (10 times higher than the amount present in the nanoparticles 
surface) of DMSA or PEG-(NH2)2, and none of them showed 
significant differences in terms of PT, aPTT and Fibrinogen by 
derived method with the control (Figure 2 D-F).  
 
Complete blood counts (CBC) studies  
Whole blood was treated with different concentrations (0.05 and 0.1 
g/L Fe) of NP-DMSA and NP-PEG-(NH2)2, and processed for CBC 
measurements.  The CBC (erythrocytes, leukocytes, platelets, 
hemoglobin and hematocrit) results did not show significant 
differences between control samples and blood treated with both 
bioferrofluids at both concentrations.  Results are shown in Figure 3 
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(A-E).  No significant differences in either hemoglobin or hematocrit 
were observed. 
The spectrophotometric study of hemoglobin in plasma 
demonstrated the absence of hemolysis for both bioferrofluids at 
these concentrations (0.05 and 0.1 g/L Fe).  Altogether these data 
show the nanoparticles safety related to erythrocytes.  Similar results 
were found with respect to platelets and leukocytes as the instrument 
did not show any flags indicating morphologic alterations or 
aggregation in any of them, reinforcing the safety of nanoparticles.  
The normal morphology of the cells was also confirmed by optical 
microscope for stained blood films (Figure 4 A-F).  Hemolyisis 
could lead to the loss of the red blood cells characteristic biconcave 
shape and spherocytes formation.  In our case, we did not observe 
smaller and denser cells than their normal counterparts in the 
samples treated with nanoparticles. 
 
 
 
 
Figure 3.  The effect of NP-DMSA and NP-PEG-(NH2)2 on hematological parameters: (A) Erythrocytes, (B) Leukocytes, (C) Platelets, (D) 
Hemoglobin and (E) Hematocrit.  Values represent mean ± SD (n=6 for bioferrofluids and 12 for control).  Effect of DMSA and PEG-(NH2)2 
as free components in hematological parameters: (F) Erythrocytes, (G) Leukocytes, (H) Platelets, (I) Hemoglobin and (J) Hematocrit.  
Values represent mean ± SD (n=4 for DMSA and PEG-(NH2)2 and 8 for control).  Control [ ], NP-DMSA [■], NP-PEG-(NH2)2 [■]. 
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CBC studies for bioferrofluids separated components (DMSA 
and PEG-(NH2)2)  
Whole blood was treated with different concentrations (0.01 and 0.1 
g/L) of DMSA and PEG-(NH2)2, and processed for CBC 
measurements.  The CBC (erythrocytes, leukocytes, platelets, 
hemoglobin and hematocrit) results did not show significant 
differences at both concentrations for blood treated with both 
materials and control.  Results are shown in Figure 3 (F-J). 
 
Figure 4. Cell morphology in presence of the nanoparticles:  (A, D), 
Stained films of untreated blood and treated blood with NP-DMSA 
(upper panel) and NP-PEG-(NH2)2 (lower panel) at concentrations 
0.05 g/L Fe (B, E) and 0.1 g/L Fe (C, F). 
 
Hemolysis studies for blood treated with NP-DMSA and NP- 
PEG-(NH2)2 
Whole blood was treated with different concentrations (0.05 and 0.1 
g/L Fe) of NP-DMSA and NP-PEG-(NH2)2, hemolysis tests did not 
show any hemolytic effect observed with naked eyes.  
Spectrophotometric measurements did not show any peak referred to 
the free hemoglobin at wavelength 580 nm as shown in Figure 5.  
These curves were consistent with their control.  These results are in 
agreement with CBC results presented above. 
In vivo studies 
The influence of DMSA and PEG coated nanoparticles in 
hematological parameters was tested in a Wistar rat animal model up 
to 30 days after administration at a single dose of 2.5 mg/kg B.W.  
Complete blood counts are summarized in Figure 6.  It was observed 
a slightly decrease in erythrocytes counts after 24 h.  Nanoparticles 
administration also showed significant differences with the control in 
the leukocytes counts in animals treated with DMSA coated 
nanoparticles at 24 h after injection.  This response is not observed 
in animals treated with PEG modified nanoparticles.  Immobilization 
of PEG on surfaces is known to decrease protein adsorption and 
subsequent immune cells recruitment.  Many models have been 
proposed to explain the mechanisms involved, but steric stabilization 
and charge shielding are the most commonly accepted.  Thus, 
chemical groups on the surface of the nanoparticles such as those 
provided by the DMSA have shown protein adsorption and 
subsequent adhesion of monocytes/macrophages28.  However, 
covalent conjugation of PEG to the free carboxyl group of DMSA 
masks surface charge (as indicated by a near neutral zeta potential) 
and creates a hydrophilic barrier that sterically prevents protein 
adsorption, reduces immunological recognition, and consequently 
the leukocyte count is not affected.  This result justified the use of 
this polymer in biomasking strategies. 
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Figure 5.  Hemolysis detection using spectrophotometer: (A,D) blood control, (B,C) blood treated with NP-DMSA at concentration 0.05 g/L 
and 0.1 g/L Fe respectively. (E) blood treated with NP-PEG-(NH2)2 at concentration 0.05 g/L Fe and (F) blood treated with NP-PEG-
(NH2)2 at concentration 0.1 g/L Fe. 
 Genotoxicity test 
Many studies have shown that nanoparticles generate reactive 
oxygen species, deplete endogenous antioxidants, alter 
mitochondrial function and produce oxidative damage in DNA29. 
Single Cell Gel Electrophoresis assay (also known as Comet Assay) 
and Micronucleus test were performed in order to analyze possible 
hematotoxicity and genotoxicity associated to magnetite 
nanoparticles administration in a Wistar rat animal model30, 31.  
Electrophoresis at high pH allows detection of single and double 
strand DNA breaks, alkali-labile sites (expressed as single-strand 
breaks), single-strand breaks associated with incomplete repair, and 
DNA–DNA or DNA–protein cross-links24, 32.  On the other hand 
Micronucleus test detects irreversible structural damages, for 
example, chromosomal damages33.  Total damage (TD %) and 
micronucleus frequencies showed no significant differences between 
the animals treated and control groups (Figure 7A) concluding that 
these bioferrofluids do not cause genotoxic effects at the analyzed 
dose. 
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Figure 6.  The effect of NP-DMSA and NP-PEG-(NH2)2 on hematological parameters.  (A) Erythrocytes, (B) Leukocytes, (C) Platelets, (D) 
Hemoglobin and (E) Hematocrit in Wistar rats after a single dose of 2.5 mg/kg.  Values represent mean ± SD (n=4). (*) marks significant 
differences between bioferrofluids and control.  Control animals were sacrificed progressively during the study and the values were averaged 
and represented with their standard deviation.  Control [ ], NP-DMSA [■], NP-PEG-(NH2)2 [■]. 
Citotoxicity test 
Bone marrow has been used for evaluation of micronucleus 
frequencies in vivo in rodents in genotoxic risk characterization but 
also as a citotoxicity test32, 34, 35.  This tissue has the most active cell 
division, therefore mutagenic or toxic effects of drugs or other 
chemicals can cause diseases like aplastic anemia, which manifests 
as the cessation of normal blood cell production; or leukemias, that 
produce excessive hematologic cancer cells36. 
In this study the ratio of polychromatic to normochromatic 
erythrocytes (PCE, NCE) was scored and the %PCE was determined 
according to the formula described in the Methods section.  Thus, no 
significant differences were observed between the animals treated 
and the corresponding control groups (Figure 7B), indicating that 
these bioferrofluids do not affect erythropoiesis or cell proliferation 
of polychromatic erythrocytes in the bone marrow at the analyzed 
dose. 
 
Conclusions 
 
Uniform magnetite nanoparticles coated with dimercaptosuccinic 
acid (DMSA) and polyethylene glycol (PEG) have been used in this 
work to assess their hematotoxicity, evaluating the blood toxicity in 
vitro and in vivo in a rat model.  
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Figure 7. Comet assay of blood samples and Micronucleus test 
of bone marrow samples.  (A) Total damage observed after 
nanoparticles administration.  (B) Ratio of immature to mature 
erythrocytes observed after nanoparticles administration at a 
dose of 2.5 mg/kg B.W.  Values represent mean ± SD (n=4). 
Dunnett´s test; significant differences with p < 0.05.  Control 
[ ], NP-DMSA [■], NP-PEG-(NH2)2 [■] 
 
The in vitro analysis consists on global plasma coagulation tests (PT, 
aPTT, Fibrinogen) and platelet aggregation while the hematotoxicity 
studies in vivo include a complete blood count and the possible 
genotoxic effects analysis in the hematopoietic function of the bone 
marrow.  In vitro analyses reveal prolonged aPTT values for NP-
DMSA compared with PEG-coated nanoparticles, which indicate 
higher anticoagulant effect for the former, probably due to a higher 
surface charge and the formation of a protein corona.  No significant 
changes were observed in the cell count, nor hemolysis for both 
bioferrofluids.  
The in vivo tests showed that these bioferrofluids do not cause 
genotoxic effects and do not affect erythropoiesis or increase the 
number of immature erythrocytes in the bone marrow at the analyzed 
dose.  However, nanoparticles administration showed a significant 
effect on the leukocytes counts in animals treated with DMSA 
coated nanoparticles 24 h after injection.  This response is not 
observed in animals treated with PEG modified nanoparticles which 
justifies the use of this polymer in biomasking strategies. 
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